L-DOPA-13C6

• UNSPSC Description:

  L-DOPA-13C6 is the 13C-labled L-DOPA[1]. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[2][3][4].

• Target Antigen:

  Dopamine Receptor; Endogenous Metabolite

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  GPCR/G Protein;Metabolic Enzyme/Protease;Neuronal Signaling

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/l-dopa-13c6.html

• Solubility:

  10 mM in DMSO

• Smiles:

  OC([C@@H](N)C[13C]1=[13CH][13C](O)=[13C]([13CH]=[13CH]1)O)=O

• Molecular Weight:

  203.14

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.|[2]Hyland K, et al. Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology. Clin Chem. 1992 Dec;38(12):2405-10.|[3]Merims D, et al. Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease. Parkinsonism Relat Disord. 200814(4):273-80. Epub 2007 Nov 7.|[4]Perez-Pardo P, et al. Additive Effects of Levodopa and a Neurorestorative Diet in a Mouse Model of Parkinson's Disease. Front Aging Neurosci. 2018 Aug 310:237.|[5]Park HJ, et al. Anti-allodynic effects of levodopa in neuropathic rats. Yonsei Med J. 2013 Mar 154(2):330-5.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  201417-12-1